Cerus Corporation Company Profile (NASDAQ:CERS)

Cerus Corporation trades on the NASDAQ under the ticker symbol "CERS."

Cerus Corporation (NASDAQ:CERS) issued its earnings results on Thursday, August, 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.16). The business earned $9.53 million during the quarter, compared to analysts' expectations of $9.14 million. Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. The company's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.18) EPS. View Cerus Corporation's Earnings History.

Cerus Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Cerus Corporation.

4 analysts have issued 1-year price targets for Cerus Corporation's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Cerus Corporation's stock price to reach $7.00 in the next year. View Analyst Ratings for Cerus Corporation.

Here are some recent quotes from research analysts about Cerus Corporation stock:

• 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (10/16/2017)
• 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $9 PT following mixed 4Q16 results and strong 2017 guidance. The company reports that 55 U.S. hospitals have begun receiving INTERCEPT platelets, with a pipeline of ~10 more expected in 1Q17 and additional hospitals expected in 2Q17. Driving that adoption is the key to 2017, in our view, and the company is sharply focused on driving hospital adoption through expanded medical science liaisons and hospital implementation teams. That said, some hospitals are already ordering as many units as are available and others are not yet in use due to capacity constraints, which we expect to be alleviated as more of the 36 installed systems come online. We continue to believe 2017 may be a breakout year as U.S. INTERCEPT utilization drives kit sales and the company progresses with both its U.S. and European red blood cell programs." (3/8/2017)

Some companies that are related to Cerus Corporation include Endologix (ELGX), RTI Surgical (RTIX), ConforMIS (CFMS), OBALON THERPTCS (OBLN), Second Sight Medical Products (EYES), Concepta PLC (CPT), Concepta PLC (FRI), Cyberonics (CYBX), HeartWare International (HTWR), St Jude Medical (STJ), Trivascular Technologies (TRIV) and Uroplasty (UPI).

Cerus Corporation's management team includes the folowing people:

• Daniel N. Swisher Jr., Independent Chairman of the Board
• William M. Greenman, President, Chief Executive Officer, Director
• Kevin D. Green, Chief Financial Officer, Vice President - Finance
• Caspar Hogeboom, President, Cerus Europe and EEMEA
• Laurence M. Corash M.D., Senior Vice President, Chief Medical and Chief Scientific Officer, Director
• Carol M. Moore, Senior Vice President - Regulatory Affairs, Quality and Clinical
• Richard J. Benjamin, Chief Medical Officer
• Vivek K. Jayaraman, Chief Commercial Officer
• Chrystal N. Menard, Chief Legal Officer and General Counsel
• Timothy Bruce Anderson, Independent Director

Shares of Cerus Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cerus Corporation stock can currently be purchased for approximately $2.99.